Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Chronic hyperglycemia impairs insulin action, resulting in glucotoxicity, which can be ameliorated in animal models by inducing glucosuria with renal glucose transport inhibitors. Here, we examined whether reduction of plasma glucose with a sodium-glucose cotransporter 2 (SGLT2) inhibitor could improve insulin-mediated tissue glucose disposal in patients with type 2 diabetes. Eighteen diabetic men were randomized to receive either dapagliflozin (n = 12) or placebo (n = 6) for 2 weeks. We measured insulin-mediated whole body glucose uptake and endogenous glucose production (EGP) at baseline and 2 weeks after treatment using the euglycemic hyperinsulinemic clamp technique. Dapagliflozin treatment induced glucosuria and markedly lowered fasting plasma glucose. Insulin-mediated tissue glucose disposal increased by approximately 18% after 2 weeks of dapagliflozin treatment, while placebo-treated subjects had no change in insulin sensitivity. Surprisingly, following dapagliflozin treatment, EGP increased substantially and was accompanied by an increase in fasting plasma glucagon concentration. Together, our data indicate that reduction of plasma glucose with an agent that works specifically on the kidney to induce glucosuria improves muscle insulin sensitivity. However, glucosuria induction following SGLT2 inhibition is associated with a paradoxical increase in EGP. These results provide support for the glucotoxicity hypothesis, which suggests that chronic hyperglycemia impairs insulin action in individuals with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Long-term effects of sodium-glucose transport protein 2 inhibitors (SGLT2i) might enhance insulin sensitivity, thereby mitigating muscle catabolism and influencing the quality and functionality of the skeletal muscle.30,31”
From Imaging of Sarcopenia in Type 2 Diabetes Mellitus (2024) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425 · cited 2×
“After the start of insulin, no glucose was infused until the plasma glucose concentration declined to 100 mg/dl, at which level it was maintained by the adjustment of a variable glucose infusion based on the negative feedback principle (27).”
Self-citationDeFronzo, R. A., Jacot, E., Jequier, E., Maeder, E., Wahren, J., & Felber, J. P. (1981) · Diabetes · doi:10.2337/diab.30.12.1000 · Cited by 1,770 · cited 1×
“Since >80% of insulin-mediated glucose disposal during the euglycemic insulin clamp takes place in skeletal muscle (16), these results indicate that lowering the plasma glucose concentration in T2DM significantly improves muscle insulin resistance and are consistent with a glucotoxic effect of chronic hyperglycemia to…”
Self-citationMeasurement of Size and Turnover Rate of Body Glucose Pool by the Isotope Dilution Method
Steele, R., Wall, J. S., de Bodo, R. C., & Altszuler, N. (1956) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1956.187.1.15 · Cited by 816 · cited 1×
“After drug administration and during the insulin clamp, nonsteady-state conditions for 3-3 H-glucose–specific activity prevail and the rate of glucose appearance ( R a ) was calculated with Steele’s equation (28).”
Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114142 · Cited by 812 · cited 1×
“However, these latter studies are difficult to interpret, since insulin therapy also exerts other metabolic effects, e.g., reduction in plasma free fatty acid concentration (12), which profoundly affect insulin sensitivity independent of changes in plasma glucose concentration (13).”
Self-citationRossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Self-citationRossetti, L., Giaccari, A., & DeFronzo, R. A. (1990) · Diabetes Care · doi:10.2337/diacare.13.6.610 · Cited by 770
Self-citationDeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90129-7 · Cited by 515 · cited 1×
“Because of the close relationship between EGP (primarily reflects liver) and the fasting plasma glucose concentration (17), the decrease in FPG brought about by dapagliflozin would be expected to be associated with a decrease in HGP.”
Self-citationBanting Lecture 1997. Control of glucose uptake and release by the liver in vivo.
Cherrington, A. D. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1198 · Cited by 502
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443 · cited 1×
“…the impact of chronic hyperglycemia on insulin sensitivity in individuals with T2DM, we examined the effect of lowering the plasma glucose concentration on whole body insulin sensitivity by inhibiting renal sodium-glucose cotransport with dapagliflozin (15) using the insulin clamp technique.”
Self-citationDose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling
Belfort, R., Mandarino, L., Kashyap, S., Wirfel, K., Pratipanawatr, T., Berria, R., DeFronzo, R. A., & Cusi, K. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1640 · Cited by 404 · cited 1×
“However, these latter studies are difficult to interpret, since insulin therapy also exerts other metabolic effects, e.g., reduction in plasma free fatty acid concentration (12), which profoundly affect insulin sensitivity independent of changes in plasma glucose concentration (13).”
Self-citation
Research works printed but not linked: 1
- Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia. 1994;37(10):1025-1035. · DOI · Paper page
Cited by
Items 601–700 of 789
Singh, A. K., Singh, A., & Singh, R. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.04.001 · Cited by 6
Lukka, P. B., Tang, W., Hammarstedt, A., Conrad, T. M., Heijer, M., Karlsson, C., & Boulton, D. W. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.07.007 · Cited by 4
Ramos-Román, M. A. (2025) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2024.0182 · Cited by 4
Popoviciu, M. S., Salmen, T., Reurean‐Pintilei, D., Voiculescu, V. M., & Stoian, A. P. (2025) · Medicina · doi:10.3390/medicina61030548 · Cited by 5
“This reduction in circulating insulin minimizes its anabolic effects on adipose tissue, further contributing to BWR [49].”
Clements, J. N., Whitley, H. P., D’Souza, J. J., Gross, B., Hess, R., Reece, S. W., Gentry, C. K., & Shealy, K. M. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1069739 · Cited by 4
Isotopic Tracers for the Measurement of Metabolic Flux Rates
Beysen, C., Hellerstein, M. K., & Turner, S. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_3 · Cited by 4
Dutta, D., & Khandelwal, D. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.167558 · Cited by 4
“[3] This increased glucagon not only leads to increased hepatic glucose output, blunting the efficacy of the drug but also leads to increased circulating glucagon/insulin ratio.[4] Increased glucagon/insulin ratio, especially in the setting of insulinopenia (sudden stoppage of insulin, uncontrolled diabetes with signi…”
Bebernitz, G. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12430-8 · Cited by 4
Morillas, C. (2016) · Medicina Clínica · doi:10.1016/s0025-7753(17)30626-7 · Cited by 4
Methods for Quantifying Insulin Sensitivity and Determining Insulin Time-Action Profiles
Krentz, A. J., Heinemann, L., & Hompesch, M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_1 · Cited by 6
“An example of the enduring utility of the hyperinsulinaemic glucose clamp is provided by a recent study which combined the technique with measurement of endogenous glucose production using 3-3H-glucose in male patients with type 2 diabetes treated for 14 days with another SGLT-2 inhibitor dapagliflozin [193].”
MethodBando, S., Ichikawa, R., Taguchi, T., Fujimoto, K., Motomiya, T., Taguchi, M., Takano, K., Shichiri, M., & Miyatsuka, T. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej21-0696 · Cited by 4
Zhou, Y., Wang, F., Wen, F.-F., Li, C., & Ye, T.-T. (2023) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2023.2250949 · Cited by 4
“Due to the hypoglycaemic effect of SGTL2 inhibition, reduced paracrine signalling associated with insulin has also been implicated as a major factor contributing to the observed increases in plasma glucagon, hepatic gluconeogenesis, and keto-genesis [32,33].”
BackgroundScarr, D., Lovblom, L. E., Ye, H., Liu, H., BAKHSH, A. M. K., Verhoeff, N. J., Wolever, T. M. S., Lawler, P. R., Sharma, K., Cherney, D. Z. I., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111031 · Cited by 4
Systems Pharmacology Modeling in Type 2 Diabetes Mellitus
Bosley, J., Maurer, T. S., & Musante, C. J. (2016) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-44534-2_20 · Cited by 4
Tratamiento de la diabetes tipo 2
Rigalleau, V., Cherifi, B. G., Blanco, L., Alexandre, L., & Mohammedi, K. (2018) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(18)89306-0 · Cited by 4
Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors
Mordi, I. R., & Lang, C. C. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.004 · Cited by 5
Schernthaner, G., & Schernthaner-Reiter, M. H. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12478 · Cited by 4
Okahata, S., Sakamoto, K., Mitsumatsu, T., Kondo, Y., Tanaka, S., & Shiba, T. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13505 · Cited by 4
Das, B., Sheikh, A., Ahmed, B., & Islam, N. (2021) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.37.5.3901 · Cited by 6
“…HbA1c and improvement in insulin sensitivity and decrease in insulin resistance along with a reduction in the beta-cell loss as reported by Merocvi A, et al. 19 make SGLT2i as a potent agent to be used in combination or as monotherapy as supported by EASD-ADA position statement for DM management.”
MethodWatanabe, Y., Kuribayashi, N., Uchida, D., Suzuki, D., Kato, M., Nagayama, D., Ohashi, H., Ohira, M., Saiki, A., & Tatsuno, I. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0555-5 · Cited by 4
LncRNA-H19 Induces Retinal Müller Cell Apoptosis via MiR-29b/FOXO4 Axis in Diabetic Retinopathy
Zhang, Q., & Wang, W. (2018) · Clinical surgery research communications · doi:10.31491/csrc.2018.12.024 · Cited by 5
Alsahli, M., & Gerich, J. E. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.03827-7 · Cited by 7
Watanabe, Y., Kuribayashi, N., Uchida, D., Suzuki, D., Kato, M., Nagayama, D., Ohashi, H., Ohira, M., Saiki, A., & Tatsuno, I. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00757-6 · Cited by 4
Larsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3
Contribution of metabolism-independent glucose sensing to metabolic homeostasis
Rashid, N., & Chhabra, K. H. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.08.008 · Cited by 3
The SGLT2 inhibitor empagliflozin promotes increased fatty acid oxidation in skeletal muscle cells
Stevanovic, S., Katare, P. B., Volledal, H. M., Bakke, H. G., Dolinar, K., Pirkmajer, S., Ouwens, D. M., Thoresen, G. H., Kase, E. T., & Rustan, A. C. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04670-2 · Cited by 3
“Moreover, dapagliflozin treatment of subjects with T2D for 5 weeks caused adaptive changes in skeletal muscle substrate metabolism in vivo favoring metabolism of fatty acids and ketone bodies, reducing amino acid levels and glycolytic flux without changes in mitochondrial integrity and function (Op den Kamp et al. 202…”
InfluentialFerreira, B., Heredia, A., & Serpa, J. (2023) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2023.112063 · Cited by 3
“…group of neoplasms that arise from multipotent stem cells in the pancreatic epithelia and the gastrointestinal system (Yalcin et al., 2017; Modlin et al., 2008). pNETs are a subtype of GEP-NETs, which derive from pancreatic endocrine cells accounting for approximately 12% of all GEP-NETs…”
SGLT inhibition in patients with type 1 diabetes
Dehn, C. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70112-3 · Cited by 3
Mooradian, A., Chehade, J. M., & Mooradian, A. D. (2015) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000161 · Cited by 3
Sodium-glucose cotransporter-2 inhibitors: Moving beyond the glycemic treatment goal
Garodia, N., Gupta, V., Canovatchel, W. J., Lokesh, B., & Santani, R. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_85_17 · Cited by 3
Kumar, S., Talwalkar, P., Das, S., & Goswami, S. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_161_17 · Cited by 3
CHADEVE, A. (2020) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2020.v13i5.36838 · Cited by 3
Barreto, J., Campos‐Staffico, A. M., Nadruz, W., Quinaglia, T., & Sposito, A. C. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1243530 · Cited by 4
Abonyi, M. C., Young, E. E., Nwatu, C. B., Ugwueze, C. V., Nkpozi, M. O., Okechukwu, U. C., Oham, M. K., Maluze, J. A., Ekochin, F. C., & Ucheze, G. G. (2023) · Nigerian Journal of Medicine · doi:10.4103/njm.njm_87_23 · Cited by 3
Quantification of Insulin Action in Human Subjects
Krentz, A. J., Weyer, C., & Hompesch, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_1 · Cited by 6
Mise au point sur le profil de tolérance de la classe des inhibiteurs de SGLT2
Gourdy, P. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30063-x · Cited by 4
Canagliflozin for Type 2 diabetes: an up-to-date evidence summary
Liakos, A., Karagiannis, T., Bekiari, E., & Τσάπας, Α. (2015) · Diabetes Management · doi:10.2217/dmt.14.59 · Cited by 5
Type 2 Diabetes Mellitus. From the start – combination therapy
Indovina, F., Falcetta, P., & Prato, S. D. (2018) · Diabetes Mellitus · doi:10.14341/dm9867 · Cited by 6
Sodium–Glucose Cotransporter 2 Inhibitors and the Kidney
DeFronzo, R. A., & Abdul‐Ghani, M. A. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0071 · Cited by 4
Self-citationLo, K. B., Iskarous, K., & Sankaranarayanan, R. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2024.12.002 · Cited by 3
Beal, B. A., Buizen, L., Yeung, E. K., Heath, L., Houston, L., Cherney, D. Z. I., Jardine, M., Pollock, C. A., Arnott, C. G., Kotwal, S. S., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf044 · Cited by 4
Checa-Ros, A., Okojie, O. J., Steib, N., Bellasi, A., Salvador-Martínez, P., Isabel, F., & D’Marco, L. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04965-6 · Cited by 2
Assessment of Islet Alpha- and Beta-Cell Function
Madsbad, S., & Holst, J. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_2 · Cited by 4
Histology of Cryopreserved Neonatal Rat Testes After Intratesticular Allotransplantation
Deng, B., Kireev, V. A., Melentyeva, K. V., Kovalenko, I., & Pakhomov, O. V. (2020) · Problems of Cryobiology and Cryomedicine · doi:10.15407/cryo30.01.034 · Cited by 2
Dapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM
Nada, A. M., & Younan, M. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821995364 · Cited by 2
The efficacy of dapagliflozin for type 1 diabetes: a meta-analysis of randomized controlled studies
Ma, J., Zhao, Y., Fan, H., & Liu, J. (2021) · African Health Sciences · doi:10.4314/ahs.v21i1.2 · Cited by 3
SGLT2 inhibitors for the treatment of diabetes: a patent review (2019–23)
Baghel, R., Chhikara, N., Kumar, P., & Tamrakar, A. K. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2379929 · Cited by 6
“Clinical investigations have revealed that SGLT2 inhibitors raise plasma glucagon levels in pancreatic α-cells [47,48].”
Ngan, J., O'Neal, D. N., Lee, M. H., Kong, Y. W., & MacIsaac, R. J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112284 · Cited by 2
Triplitt, C. L., Cersósimo, E., Alatrach, M., Adams, J. M., HANSIS-DIARTE, A. A., Baskoy, G., Gastaldelli, A., Chavez-Velazquez, A., & DeFronzo, R. A. (2025) · Diabetes Care · doi:10.2337/dc25-0490 · Cited by 3
Self-citationIs there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors
KHAKDE, S., Jawaid, H., Yasmin, F., Ali, M. B., & REHMAN, A. (2022) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03221-6 · Cited by 2
The Non-glycemic Effects of SGLT2 Inhibitor
Lee, D. H. (2014) · Journal of Korean Diabetes · doi:10.4093/jkd.2014.15.3.151 · Cited by 2
Meier, J. J., & Nauck, M. A. (2020) · Endocrinology · doi:10.1210/endocr/bqaa107 · Cited by 2
The world congress on insulin resistance, diabetes, and cardiovascular disease ( WCIRDC )
Bloomgarden, Z. T. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13260 · Cited by 2
Метаболічні ефекти інгібіторів натрійзалежного котранспортера глюкози 2 типу
Кедик, А. В., & Kutsin, O. O. (2022) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2022-4-42 · Cited by 2
Besmaya, B. M., & Laksono, S. (2023) · MPI (Media Pharmaceutica Indonesiana) · doi:10.24123/mpi.v5i1.5266 · Cited by 7
“Setelah 4 minggu, oksidasi glukosa turun sebesar 60% dan oksidasi lemak meningkat sampai 20% [28,29].”
Yamada, T., Sugimoto, H., Hironaka, K., Morita, Y., Miura, H., Otowa‐Suematsu, N., Okada, Y., Hirota, Y., Sakaguchi, K., Kuroda, S., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae067 · Cited by 1
“In addition to their hypoglycemic action due to the promo-under specific conditions [9-12].”
BackgroundSGLT2 Inhibitors Therapy in Type 2 Diabetes Mellitus
Ahmad, M. M., Brema, I. A., & Almalki, M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84152 · Cited by 3
Kurozumi, A., Okada, Y., Shimokawa, M., Goshima, Y., Otsuka, T., Narisawa, M., Torimoto, K., & Tanaka, Y. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0099 · Cited by 2
FULMINANT MYOCARDITIS-A UNIQUE COMPLICATION OF COVID-19
Ahmed, A., Young, S. K., & Lantz, R. H. (2021) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(21)03378-7 · Cited by 2
Iijima, T., Hosonuma, S., Kurai, H., Kajitani, H., Sakurai, S., Tomaru, T., Jojima, T., Usui, I., & Aso, Y. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14732 · Cited by 2
Bailey, C. J., & Krentz, A. J. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch31 · Cited by 2
Neeland, I. J., Kasai, T., Inzucchi, S. E., Wojeck, B. S., Yaggi, H. K., & Johansen, O. E. (2021) · Diabetes Care · doi:10.2337/dci21-0009 · Cited by 2
Valdez, I. A., Palavicini, J. P., Bakewell, T. M., Fourcaudot, M. J., Ayala, I., Xu, Z., Khattab, A., Han, X., Shannon, C. E., & Norton, L. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.31.494168 · Cited by 3
Self-citationSchernthaner-Reiter, M. H., & Schernthaner, G. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1151783 · Cited by 1
Glucagon and the metabolic syndrome
Welch, A., & Vella, A. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00011-6 · Cited by 2
Daniele, G., Tura, A., Brocchi, A., Saba, A., Campi, B., Sancho‐Bornez, V., Dardano, A., & Prato, S. D. (2024) · Diabetes Care · doi:10.2337/dc23-2051 · Cited by 1
Self-citationAkamine, M. A. V., Soares, B. M. A. F., Telles, J. P. M., de Assis, A. C. R., Rodriguez, G. N. V., Soares, P. R., Chalela, W. A., & Scudeler, T. L. (2024) · Pharmaceuticals · doi:10.3390/ph17070920 · Cited by 1
Prediabetes and CKD: Does a causal relationship exist
Rico-Fontalvo, J. E., Soler, M. J., Daza-Arnedo, R., Navarro‐Blackaller, G., Medina-González, R., Yánez, T. R., Cardona-Blanco, M., Cabrales, J., Uparrela-Gulfo, I., & Chavez-Iñiguez, J. S. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.11.005 · Cited by 9
Future Perspectives in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_6 · Cited by 2
Petersen, M. C., Jones, K. E., Markov, A. M., Salam, M., Krutilova, P., McKee, A. M., Bohnert, K. L., Adamson, S. E., & McGill, J. B. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16324 · Cited by 1
“22 Hyperglucagonemia induced by SGLT2 inhibition 23 could also drive ketogenesis.”
Sutcliffe, C., Sargeant, J. A., Yates, T. E., Davies, M. J., & Baker, L. A. (2025) · Frontiers in Systems Biology · doi:10.3389/fsysb.2025.1593229 · Cited by 2
Miyamoto, L., Nakayama, S., Endoh, H., Fujiwara, K., Hattori, M., Yasuoka, T., Imanishi, M., Ikeda, Y., & Tsuchiya, K. (2026) · HORMONES · doi:10.1007/s42000-026-00805-z · Cited by 1
Liu, P., Kadier, K., Wu, X., Sun, X., Zhang, G., Liu, X., Song, D., & Cui, C. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1658286 · Cited by 1
Yagi, T., Aotani, D., Hasegawa, C., Shimizu, Y., Koyama, H., Maezawa, Y., Yokote, K., & Tanaka, T. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70203 · Cited by 1
“In patients with type 2 diabetes, SGLT2 inhibitors improve glycemic control not only through their canonical urinary glucose disposal, but through an improvement of insulin sensitivity in skeletal muscles 5 .”
Neshat, S., Moradi, H., Bidares, M., Heidari, A., Marvast, A. F., Ortega, R., & Heshmat, K. (2025) · Cureus · doi:10.7759/cureus.99752 · Cited by 2
The Use of Dapagliflozin in the Treatment of Children With Severe Insulin Resistance
Attia, N., Noaim, K. I. A., Khadora, M. M., Fifi, S. H. A., Alwan, I. A. A., Thalange, N. K. S., & Babiker, A. M. I. (2025) · Pediatric Diabetes · doi:10.1155/pedi/6859764 · Cited by 1
“This leads to improved insulin-mediated glucose disposal and overall sensitivity [18].”
Hällbom, M., Lindåse, S. S., Wartel, M., & Bröjer, J. T. (2026) · Equine Veterinary Journal · doi:10.1002/evj.70181 · Cited by 1
Montasser, M. E., Bargal, S. A., Streeten, E. A., Whitlatch, H. B., Yazdi, Z. S., Sirody, J., Kiplagat, R., Beshara, M., O’Connell, J. R., Taylor, S. I., et al. (2026) · Clinical and Translational Science · doi:10.1111/cts.70594 · Cited by 1
Gao, R., Spiliotis, I., Dou, H., Hill, T. G., Kothegala, L., MIRANDA, C. A., Abiakam, N., Coleman, R. L., White, S., Adler, A., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106298 · Cited by 2
“Given published reports that SGLT2 inhibitors increase glucagon secretion both in vivo and in vitro, 17,31,32 we also tested whether a single dose of dapagliflozin would restore glucagon secretion during hypoglycaemia in people with T1D.”
Rebelos, E., & Honka, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71205 · Cited by 1
“Moreover, although glucose levels were clamped, it remains unknown whether [ 18 F]FDG availability in plasma differed between groups, particularly since some—but not all—studies suggest that SGLT2 inhibitors may improve insulin sensitivity [3, 4].”
Svonni, E., Lindåse, S., Hanche-Olsen, S., Hellings, I. R., Fintl, C., Nostell, K., & Bröjer, J. (2026) · Journal of Veterinary Internal Medicine · doi:10.1093/jvimsj/aalag249 · Cited by 1
“32 , 34 , 49 Similar responses in insulin secretion obser ved in humans with metabolic syndrome characterized by insulin resistance and in horses with ID support the hypothesis that insulin resistance may be an important component of ID in horses.”
Okada, S., Shibusawa, R., Tagaya, Y., Saito, T., Yamada, E., Shimoda, Y., Satoh, T., Okada, J., & Yamada, M. (2014) · Journal of Medical Case Reports · doi:10.1186/1752-1947-8-428 · Cited by 1
Empagliflozin and metformin combination therapy in Type 2 diabetes mellitus
Jeyalalitha, R. (2015) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20151382 · Cited by 2
Basile, J. (2016) · Hospital Practice · doi:10.1080/21548331.2016.1141656 · Cited by 2
Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes
Steinberg, H. O. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1168687 · Cited by 2
Euglycemic diabetic ketoacidosis with SGLT2 inhibitors in lean type 2 diabetes
Kim, M.-K. (2016) · Integrative Obesity and Diabetes · doi:10.15761/iod.1000157 · Cited by 1
SGLT2 Inhibitors and Ketoacidosis: Pathophysiology and Management
Ku, Y. H. (2017) · Korean Journal of Medicine · doi:10.3904/kjm.2017.92.5.443 · Cited by 1
Nakamura, Y., Horie, I., Tashiro, S., Kobayashi, M., Kitamura, T., Kusunoki, Y., Nishida, K., Yamamoto, A., Hirota, Y., Fukui, T., et al. (2021) · Medicine Case Reports and Study Protocols · doi:10.1097/md9.0000000000000135 · Cited by 2
Alsahli, M., & Gerich, J. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-20797-1_2-1 · Cited by 1
Euglycemic Diabetic Ketoacidosis in a Diabetic Patient Treated with SGLT2 Inhibitor
Lavrynenko, O., Hector, S., Amando, G., Qazi, R., & Leopoldo, C. (2021) · Clinical Diabetes and Research · doi:10.36959/647/497 · Cited by 1
Bogowska, M., Berner, A., MARCZYK, K., MATYJA, K., OLSZEWSKA, A., PĘKAŁA, M., Polak, P., POLASZEK, M., Stelmaszak, K., & Stencel, K. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.38.01.013 · Cited by 1
“[89, 90, 91] It is important to test urine and plasma ketons at”
BackgroundWatanabe, K., Yamaguchi, S., Kosakai, Y., Ioji, T., & Ishihara, H. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01317-z · Cited by 1
“Increased plasma glucagon levels were first reported in patients receiving treatment with SGLT2is [27, 28] but the effect has not been attributed to a direct action of SGLT2is.”
BackgroundHaddadin, R. W., Aboujamra, D., & Iraninezhad, H. (2023) · Cureus · doi:10.7759/cureus.51184 · Cited by 3
“Cited literature shows glucagon and endogenous glucose levels increase after dapagliflozin use [17].”
Ketonuria in an adult with Prader-Willi syndrome and diabetes mellitus: A case report
Xu, X., Wang, D., Pan, H., Li, J., Li, B., & He, Z. (2024) · Medicine · doi:10.1097/md.0000000000037096 · Cited by 1
“[10,11] Besides, the SGLT-2 inhibitor itself stimulates glucagon secretion, [12,13] further enhancing lipolysis and ketogenesis.”
BackgroundDeshmukh, N., Kalshetti, M. S., Patil, M., Autade, P., & Sangle, G. V. (2024) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13854 · Cited by 1
“As inhibition of SGLT2 is reported to stimulate the glucagon release, 30,41,42 we hypothesise the involvement of glucagon in lipid handling by sotagliflozin.”
BackgroundDehydration-induced AVP stimulates glucagon release and ketogenesis
Hill, T. G., Briant, L. J. B., Kim, A., Wu, Y., Rorsman, P., Asterholm, I. W., & Benrick, A. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00505.2024 · Cited by 5
Les acidocétoses diabétiques atypiques
Schlienger, J.-L., & Halimi, S. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30118-3 · Cited by 4
Park, S. H., Choi, Y. J., Rhee, E., & Huh, K. B. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.1.70 · Cited by 1
Sander, G. E., Fernandez, C., Kadowitz, P. J., & Giles, T. D. (2016) · Hypertension Journal · doi:10.5005/jp-journals-10043-0046 · Cited by 1
Kusunoki, M., Sato, D., Sakazaki, T., Miyata, T., Tsutsumi, K., & Oshida, Y. (2020) · Drug Research · doi:10.1055/a-1070-8783 · Cited by 1
Metadata
- Authors
- Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., & DeFronzo, R. A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, Ralph A.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-01-27
- Volume
- 124
- Issue
- 2
- Pages
- 509-514
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3904617
- OpenAlex
- W2166613497
- Cited by
- 795
- References
- 28
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 52 · 2023: 55 · 2022: 64 · 2021: 58 · 2020: 91 · 2019: 63 · 2018: 71 · 2017: 71 · 2016: 79 · 2015: 82 · 2014: 43
- FWCI
- 73.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- National Institutes of Health (UL1TR001120, 5R01DK240923, KL2TR001118)
- University of Texas Health Science Center at San Antonio
- National Institute of Diabetes and Digestive and Kidney Diseases (5R01DK240923, R01DK024092)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, skeletal muscle insulin sensitivity, endogenous glucose production, glycosuria, glucotoxicity, hyperglycemia, insulin-stimulated glucose disposal, glucagon, renal glucose transport
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Fasting, Glucagon, Glucose, Glucosides, Humans, Hyperglycemia, Insulin, Male, Metformin, Middle Aged, Muscles, Sulfonylurea Compounds, Time Factors, Glucose Clamp Technique, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.